Oncology & Hematology | Allucent
Home  /  Therapeutic Expertise  /  Oncology & Hematology

Oncology & Hematology

Partnering to overcome the complex challenges in oncology studies throughout the lifecycle of your product

SCROLL

Oncology remains one of the most challenging therapeutic areas, with the lowest success rates in clinical trials. This underscores the need for innovative strategies and a partner who understands the complexities of this field and has deep experience across all stages of development.

Combining clinical expertise with research is essential for driving innovation and effective therapies. By aligning with scientific advancements and regulatory standards, we streamline development, accelerating safe treatments in hematology and oncology. This integration ensures faster patient access to transformative care while maintaining the highest safety standards.

Oksana Fabri, PhD, MD

Sr. Medical Director, Therapeutic Area Medical Lead, Hematology/Oncology

Preclinical Phase

Phase I (First-in-Human)

Phase II (Efficacy & Dose-Ranging)

Phase III (Pivotal Studies)

Phase IV (Post-Approval Activities)

Preclinical
Phase

  • Expertise in toxicology studies and pharmacokinetics to ensure a smooth transition to clinical trials
  • Strong support for IND submissions with regulatory agencies (FDA, EMA, etc.)
  • Deep experience in biomarker discovery and target identification to accelerate drug development

Phase I (First-in-Human)

  • Proven track record in dose-escalation and safety-focused trials, particularly in oncology
  • Expertise in designing and conducting adaptive trial designs, especially for novel oncology therapies
  • Strong emphasis on site selection early patient engagement for efficient trial execution

Phase II (Efficacy & Dose-Ranging)

  • Deep understanding of biomarker-driven patient selection to increase trial success rates
  • Expertise in innovative trial designs (e.g., basket trials, single-arm trials) for faster efficacy evaluation
  • Strong collaborations with KOLs and oncology research sites to ensure high-quality data and recruitment (key activity in Phase I as well)

Phase III (Pivotal Studies)

  • Proven success in managing multi-center, global oncology trials with complex regulatory requirements
  • Extensive experience with comprehensive trial management, including risk-based monitoring and data-driven decision-making
  • Robust capabilities in handling regulatory submissions, including NDA/BLA and marketing approval strategies

Phase IV (Post-Approval Activities)

  • Comprehensive lifecycle management: Focused on pharmacovigilance for product safety and on ensuring compliance and inspection readiness
  • Expertise in label expansions, new indications, and global approvals to extend product reach
  • Support for market access and ongoing commercialization to ensure long-term success

Oncology Trials Require Multilayered Expertise

We have the hands-on knowledge to manage the complexities of cancer research and provide full-service support across various therapeutic areas. Our extensive experience across Early Phase through Phase III trials and beyond spans a wide range of oncology and hematology indications.

260+

Studies

3,900+

Sites

24,000+

Patients

40+

Countries

All-time years of experience

With global breadth and depth across a wide range of oncology and hematology indications, Allucent partners with biotech companies to bring innovative therapies to light.

SOLID TUMORS

Open Close
  • All comer (all solid tumors)
  • Brain tumors (including GBM)
  • Bladder cancer
  • Breast cancer
  • Cervical cancer
  • Colorectal cancer
  • Endometrial cancer
  • Gastric cancer
  • Head and neck cancer
  • Liver cancer
  • Lung cancer (including NSCLC)
  • Melanoma
  • Neuroendocrine tumors
  • Ovarian cancer
  • Pancreatic cancer
  • Prostate cancer
  • Renal cancer
  • Sarcoma

HEMATO-ONCOLOGY

Open Close
  • All comer (all hemato-oncology)
  • Acute lymphoblastic leukemia (ALL)
  • Acute myeloid leukemia (AML)
  • Chronic lymphocytic leukemia (CLL)
  • Chronic myeloid leukemia (CML)
  • Lymphoma
  • Multiple myeloma
  • Myelofibrosis
  • Myelodysplastic syndromes
  • Graft versus host disease
  • Veno-occlusive disease

HEMATOLOGY

Open Close
  • Anemia
  • Anticoagulant reversal
  • Autoimmune hemolytic anemia
  • Blood loss
  • Essential thrombocythaemia
  • Graft versus host disease
  • Hereditary angioedema
  • Hyperbilirubinemia (genetic)
  • Neutropenia
  • Paroxysmal nocturnal
  • Sickle cell anemia
  • Thrombotic thrombocytopenic purpura (TTP)

BIOLOGICALS

Open Close
  • Antibodies (e.g., monoclonal, bi-specific, antibody drug conjugates (ACDs), checkpoint inhibitors)
  • Peptides
  • Cell-based
  • Autologous & allogenic (e.g., dendritic cell (DC), natural killer (NK), T cell, stem cell)
  • Hormonal (e.g., hormone receptor inhibitors, liposomal corticosteroids)
  • Vaccines (e.g., bacterial vaccines, DNA vaccines, peptide vaccines, RNA vaccines, tumor-derived vaccines)
  • Oncolytic viruses
  • Radiolabeled compounds

OLIGONUCLEOTIDES

Open Close
  • Antisense oligonucleotides
  • miRNA compounds

SMALL MOLECULES

Open Close
  • Chemotherapy (e.g., alkylating agents, anthracyclines, antimetabolites, anti-microtubule agents, taxanes, topoisomerase inhibitors)
  • Inhibitors (e.g., angiogenesis inhibitors, HDAC inhibitors, integrin receptor antagonists, PARP inhibitors, protein kinase inhibitors, tyrosine kinase inhibitors (TKIs)

Meet Some of Our Oncology and Hematology Experts

Brian Abbott, MD

Executive Medical Director,
Therapeutic Area Medical Lead,
Oncology/Hematology

Brian Abbott, MD - LinkedIn Page

Brian Barnett, MD

Executive Medical Director,
Medical Affairs

Brian Barnett, MD - LinkedIn Page

Oksana Fabri, PhD, MD

Sr. Medical Director,
Therapeutic Area Medical Lead,
Hematology/Oncology

Oksana Fabri, PhD, MD - LinkedIn Page

Sandra Olthof

Global Operations Head,
Oncology/Hematology

Sandra Olthof - LinkedIn Page

Allucent Center of Expertise (ACE): Oncology & Hematology

Pioneering Cancer Therapies for Tomorrow's Cures

We have extensive experience with both traditional and cutting-edge therapies, including molecularly targeted agents, immunotherapies, and cell and gene therapies. We also specialize in combination therapies, and have substantial experience with anticancer vaccines, antibodies (monoclonal, bispecific, and ADCs), nanoparticle formulations, and modified chemotherapies to improve efficacy and patient outcomes.

Click icons for more information:

Comprehensive Expertise Across Traditional and Advanced Therapies in Oncology

Related Content

Additional Resources

Partner With the A-Team

Let us know how we can help you bring new therapies to light. Get in touch to get started.

Join the A-Team

Want to help small and mid-sized biotech companies change the therapeutic landscape?

Subscribe to our monthly newsletter